Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LABT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsLakewood-Amedex appoints biotech veteran Dr. Joseph Tucker to Board of Directors
Filed April 28, 2026 · Period ending April 24, 2026 · ~1 min read
Key Changes
-
medium
Dr. Joseph Tucker, CEO of Enveric Biosciences with experience raising $100M+ and executing IPOs and M&A, joins LABT's Board effective April 24, 2026. He will serve on Finance, Audit, Compensation, and Governance committees until the 2027 annual meeting.
Item 5.02 verify on EDGAR → -
low
Tucker receives $6,000 quarterly compensation paid in common stock shares, plus 33,784 warrants exercisable at $10.00 per share with 10-year term, vesting quarterly over two years in four equal tranches of 8,446 warrants each.
Item 5.02 verify on EDGAR → -
low
Board Agreement requires Tucker to attend 2-4 Board meetings annually and be available for ad-hoc consultations, with reimbursement for pre-approved travel expenses. Agreement continues indefinitely unless terminated by either party.
Item 5.02 verify on EDGAR →
Summary
Lakewood-Amedex Biotherapeutics added experienced biotech executive Dr. Joseph Tucker to its Board of Directors, filling a vacancy effective April 24, 2026. Tucker brings significant public company leadership experience as current CEO of Enveric Biosciences, having raised over $100 million in capital and executed strategic transactions including IPOs and mergers.
He will serve on all four Board committees through the 2027 annual meeting. For retail investors, this appointment signals LABT's effort to strengthen governance and strategic oversight with proven biotech sector expertise. Tucker's compensation is modest—$6,000 per quarter in stock plus warrants exercisable at $10.00 per share—suggesting alignment with shareholder interests rather than excessive dilution.
The warrant strike price of $10.00 provides a benchmark for where the Board values near-term upside. Watch for Tucker's impact on capital allocation and strategic direction at upcoming Board meetings. His track record in raising capital and executing transactions could indicate LABT is positioning for financing activities or business development moves in the coming quarters.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Lakewood-Amedex appointed Dr. Joseph Tucker to its Board of Directors, effective April 24, 2026, with quarterly stock compensation and warrants.
Added in current filing · verify on EDGAR →
On April 24, 2026, the Board of Directors (the “Board”) of Lakewood-Amedex Biotherapeutics Inc. (the “Company”) appointed Dr. Joseph Tucker to fill a vacancy and serve as a member of the Board, effective April 24, 2026. He will serve until the Company’s 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.
The Company appointed Dr. Joseph Tucker, age 57, to its Board of Directors to fill a vacancy. Dr. Tucker currently serves as CEO and Director of Enveric Biosciences and has extensive experience leading public biotechnology companies, raising over $100 million in capital, and executing strategic transactions including IPOs and M&A. He will serve on the Finance, Audit Committee and Risk Committee, Compensation Committee and Corporate Governance and Nominating Committee.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In connection with Dr. Tucker’s appointment to the Board, the Company and Dr. Tucker entered into a board agreement, dated April 24, 2026 (the “Board Agreement”), which provides among other terms that Dr. Tucker will attend up to four, but no fewer than two, meetings of the Board per year and to be available for ad-hoc phone or email consultations throughout the year. The Company has agreed to reimburse Dr. Tucker for reasonable pre-approved travel and living expenses incurred in connection with Board meetings. The Board Agreement continues indefinitely unless terminated by either party.
The Board Agreement requires Dr. Tucker to attend between two and four Board meetings annually and be available for ad-hoc consultations. The Company will reimburse reasonable pre-approved travel and living expenses. The agreement continues indefinitely unless either party terminates it, and includes customary confidentiality, work product ownership, and a twelve-month post-service non-solicitation covenant.
Event · Item 9.01 — Financial Statements and Exhibits
LABT filed exhibits for Board Agreement and Warrant Agreement with Joseph Tucker, announced via press release.
Added in current filing · verify on EDGAR →
Board Agreement with Joseph Tucker
The company entered into a Board Agreement with Joseph Tucker. The 8-K lists this as Exhibit 10.1 but does not provide details about Tucker's role, compensation, or terms within the filing body itself.
Added in current filing · verify on EDGAR →
Warrant Agreement with Joseph Tucker
The company entered into a Warrant Agreement with Joseph Tucker. The 8-K lists this as Exhibit 10.2 but does not disclose warrant terms, strike price, quantity, or vesting conditions within the filing body.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify